Table 8.1

Drug-specific and patient factors to consider when selecting antihyperglycemic treatment in adults with type 2 diabetes

Embedded Image
  • *See ref. 31 for description of efficacy. †FDA approved for CVD benefit. CVD, cardiovascular disease; DKA, diabetic ketoacidosis; DKD, diabetic kidney disease; NASH, nonalcoholic steatohepatitis; RAs, receptor agonists; SQ, subcutaneous; T2DM, type 2 diabetes.